As a confirmation of this, it was recently demonstrated that activation of MEK in BRAFmut cells promotes the development, growth, and maintenance of melanoma in vivo when PTEN and/or CDKN2A losses coexist [35]. This evidence concerns the gene PTEN and melanoma.